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Background: The aim of screening for colorectal cancer is to improve prognosis by the
detection of cancer at its early stages. In order to inform the decision on the speciﬁc test
to be used in the population-based program in the Basque Autonomous Region (Spain),
we compared two immunochemical fecal occult blood quantitative tests (I-FOBT).
Methods: Residents of selected study areas, aged 50–69 years, were invited to participate
in the screening. Two tests based on latex agglutination (OC-Sensor and FOB Gold) were
randomly assigned to different study areas. A colonoscopy was offered to patients with
a positive test result. The cut-off point used to classify a result as positive, according to
manufacturer’s recommendations, was 100 ng/ml for both tests.
Results:The invited population included 37,999 individuals. Participation rates were 61.8%
(n = 11,162) for OC-Sensor and 59.1% (n = 11,786) for FOB Gold (p = 0.008). Positive rate
for OC-Sensor was 6.6% (n = 737) and 8.5% (n = 1,002) for FOB Gold (p < 0.0001). Error
rates were higher for FOB gold (2.3%) than for OC-Sensor (0.2%; p < 0.0001). Predictive
positive value (PPV) for total malignant and premalignant lesions was 62.4% for OC-Sensor
and 58.9% for FOB Gold (p = 0.137), respectively.
Conclusion: OC-Sensor test appears to be superior for I-FOBT-based colorectal cancer
screening, given its acceptance, ease of use, associated small number of errors and its
screening accuracy. FOB Gold on the other hand, has higher rate of positive values, with
more colonoscopies performed, it shows higher detection incidence rates, but involves
more false positives.
Keywords: immunochemical fecal occult blood test, population screening, health outcomes research, health impact
assessment, colorectal cancer
INTRODUCTION
Colorectal cancer (CRC) is the third leading cancer and the fourth
leading cause of cancer deaths worldwide, with 1.2 million esti-
mated new cases and 609,000 estimated deaths in 2008 (Karsa
et al., 2010). In the European Union (EU), as well as in Spain,
CRC is the third leading newly diagnosed cancer, after lung cancer
and prostate cancer in males and the second after breast cancer
in females and the second leading cause of overall cancer deaths
(Karim-Kos et al., 2008). Due to its high frequency, mortality and
morbidity rates, and the high socio-economic burden associated
with this disease, CRC has become an important and challenging
public health problem (Karsa et al., 2010).
In the Basque Country (one of 17 Autonomous Regions of
Spain), once age-adjusted at European standard population, CRC
incidence (86.37/100,000 among men and 39.75/100,000 among
women in 2009), and mortality rates (20.6/100,000 in 2009), have
shown moderate increases, mainly in men from 1986 to 2008
(Izarzugaza et al., 2010).
Nowadays, a substantial amount of information is available on
CRC etiology and prognosis. Its slow growth from benign lesions
is currently well known and this makes many of these lesions
detectable and removable at an early stage (Scottish Intercollegiate
Guidelines Network [SIGN], 2011).
Primary prevention is based mainly on the adoption of healthy
lifestyle measures including changes in dietary habits (Kahi et al.,
2008). However, the beneﬁts of both healthy lifestyle measures
become visible in the long-term. It is therefore necessary to design
and implement programs that allow early detection and manage-
ment of pre-cancerous and cancer lesions (secondary prevention;
von Karsa et al., 2008).
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The new European Code against Cancer (2003/878/EC;
European Code Against Cancer, 2012) includes among its
recommendations that “men and women from 50 years of age
and older should participate in CRC screening.” Both the EU
and the Comprehensive Cancer Plan of the Spanish Ministry of
Health, Social Services and Equity (2006; Ministerio de Sanidad
y Política Social, 2010) include the implementation of screen-
ing programs among their recommendations for CRC prevention.
Nationwide CRC screening programs are currently being imple-
mented in several European countries as well as Spain. Effective
screening methods have been shown to decrease CRC incidence
rates by 20% and mortality rates by 33% (Mandel et al., 1993;
Shaukat et al., 2013).
Up to now, the guaiac fecal occult blood test (g-FOBT) was
considered the standard screening test used in CRC detection
programs. However, recently marketed immunochemical tests
(I-FOBT) have become widely accepted due to several advan-
tages over g-FOBT (Rozen et al., 2009; Oono et al., 2010), and
its use is recommended for population-based programs (Segnan
et al., 2011). Advantages include a higher sensitivity, speciﬁcity
for human hemoglobin (Allison et al., 2007), fewer stool sam-
ples required and no diet or medications restrictions are needed.
Additionally, the quantitative nature of I-FOBT results allows for
an optimal cut-off point to be set for a nationwide screening
program (Castiglione et al., 2002; Wong et al., 2003; Fraser et al.,
2006; Guittet et al., 2007; Levi et al., 2007), based on pre-speciﬁed
criteria.
Adherence rate is of paramount importance to ensure CRC
screening programs effectiveness. In this sense, immunochemi-
cal tests show higher adherence (Cole et al., 2003; Van Rossum
et al., 2008; Hol et al., 2010) and detection rates (Smith et al., 2006;
Guittet et al., 2007; Van Rossum et al., 2008) than g-FOBT.
The I-FOBT testing samples can be analyzed automatically,
which involves important advantages in terms of quality assurance
and costs (Levi et al., 2007).
The Basque Ministry of Health approved in 2008 the imple-
mentation of a population-based screening program through the
detection of fecal occult blood (FOB) using I-FOBT as the screen-
ing method every 2 years and colonoscopy as a conﬁrmation test.
An important issue to be dealt with was decision on the particular
I-FOBT to be used as two commercial diagnostic kits were avail-
able in the Spanish market at the time screening activities were
about to start.
A comprehensive literature search did not yield consistent
information regarding comparison of analytical and operational
characteristics among marketed immunochemical tests. Just one
journal article addressing the compared diagnostic efﬁcacy of two
different I-FOBTs was found, with no deﬁnitive results (Rubeca
et al., 2006).
Therefore, we aimed to compare the two available I-FOBT tests:
OC-Sensor (Eiken Chemical Co., Tokyo, Japan) and FOB Gold
(Sentinel Diagnostics SpA, Milan, Italy) in terms of diagnostic
performance, ease of use, acceptance, and operational features
within the context of the pilot phase of a CRC population-based
screening program. The outcomes of that studywould then inform
the decision-making process to choose the screening test for the
ulterior full implementation.
METHODS
This study involved the ﬁrst round of a CRC population-based
screening program in the Basque Country – restricted to some
previously determined health districts – from January 2009 to
March 2010, and invited residents aged 50–69, from the Basque
Health Service database (n = 37,999). People with colorectal can-
cer resection (CCR) history and who had undergone a previous
colonoscopy within the past 5 years were excluded.
Participation was voluntary and was offered to all subjects res-
idents who lived in the areas designated for the study and had a
general practitioner (GP) assigned.
The Screening Management Centre sent a letter explaining the
aims and methods of the screening program to all eligible subjects.
After 7–10 days, a second letter was sent with a request for them
to participate in the program, including a kit package speciﬁcally
suited to collect a single sample of feces, and stickers with the
uptake’s data to be attached to the tube. Participants could leave
the kit sample at the Primary Care Centers during working hours
(from 8:00 am to 8:00 pm). Samples were processed by trained
laboratory staff following the instructions provided by the manu-
facturers. At health-district level, neither health professionals nor
administrative staffs were aware that a comparison of screening kit
tests was being conducted. Each assay test was randomly assigned
by an independent researcher to each of ﬁve health districts where
the program was being implemented. According to both man-
ufacturer’s instructions, tests were considered positive when the
sample contained at least 100 ng/ml of hemoglobin by buffer. A
colonoscopy was offered to all positive participants by their GP.
When errors were identiﬁed by any laboratory before or after ana-
lyzing the sample, a new kit was sent to the participant and the
new sample analyzed. True positives were deﬁned by colonoscopy
examination and pathology analysis. CRC screening performance
measures were assessed following the National Guidelines pub-
lished in 2009 (Castells et al., 2009). Every case was codiﬁed by
expert staff in the Screening Management Centre. Advanced ade-
noma was considered: >10 mm, or 3–10 adenomas or villous
morphology, or high degree of dysplasia. Cancer colorectal was
considered pT1.
This studywas conducted under real practice conditions, which
is why we did not perform colonoscopies for patients with a neg-
ative FOBT test. To control the false negatives interval cancers are
followed, as recommended by the EuropeanGuidelines (vonKarsa
et al., 2008).
The study was submitted and approved by the Ethics Commit-
tees of screened areas.
STATISTICAL ANALYSIS
Colorectal cancer screening performance measures were assessed
following the European Guidelines (Segnan et al., 2011). Chi-
square tests were used to compare proportions between relevant
subgroups. Log-binomial regressionmodels (Barros andHirakata,
2003)were ﬁtted to yield age and sex-adjusted comparisons among
assessed kits, in terms of corresponding participation rates, pos-
itive predictive values, error rates, and cancer and advanced ade-
nomas incidence rates. In order to assess magnitude and statistical
signiﬁcanceof the effects of predictors of interest, averagemarginal
effects (AME; mean change in predicted probabilities of the
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response variable across all sampled individuals when the categori-
cal predictor changes byone levelwith respect to the reference level,
keeping all other predictors at observed values) were calculated
(Bartus, 2005). In some instances, to provide additional informa-
tion on the magnitude of effects, relative estimates are given in
the form of relative risks (RR) as estimates of prevalence ratios.
Standard errors that took the cluster (health district assignment of
kits) structure of the data into account were estimated using the
delta method. Estimated models included statistically signiﬁcant
interactions. As gender–age group interactions were most often
encountered, AME are shown by gender and age stratum combi-
nations to ease interpretation of effects. Signiﬁcance level was set
to 5%.
Statistical analyses were performed using Stata 12 for Windows
(StataCorp. 2011. Stata Statistical Software: Release 12. College
Station, TX: StataCorp LP).
RESULTS
PROGRAM COVERAGE
The target population included 39,566 individuals. Finally, a
total of 37,999 individuals aged 50–69 and who met the partic-
ipation criteria, were invited to participate. Table 1 shows the
characteristics of this population and performed procedures. Sta-
tistically signiﬁcant differences in age distribution were found
between invited individuals assigned to the study kits [mean age
for population receiving FOB Gold 58.6 years (SD: 5.6) and 59.1
(5.8) for population receiving OC-Sensor; p = 0.000]. The same
pattern of overall and strata-based age differences was found
between individuals of both participants groups [mean age for
FOB Gold 58.9 (5.5) and 59.5 (5.7) for OC-Sensor]. No statis-
tically signiﬁcant differences were found in gender distribution
between invited people (50.2% of people receiving FOB Gold
test were women vs. 50.8% in population receiving OC-sensor;
p = 0.233).
Overall participation rate was 60.4% (OC-Sensor assay 61.8%
vs. 59.1% for the FOB Gold, p = 0.008). It was consistently and
signiﬁcantly higher for females with an overall marginal effect
estimate of 6.8% increase in participation rate relative to men
(Tables 2 and 3). Participation ratewithOC-Sensor test was higher
for both sexes (65.1 vs. 62.6% in women and 58.3 vs. 55.6% in
men) and kept consistently higher (range of differences: 1.5–3.5%)
across all age groups. However, this difference was not statistically
signiﬁcant when the cluster-randomized design was accounted for
in the analysis (RR= 1.05; 95%CI= 0.93–1.18) Participation rates
increased signiﬁcantly with age in both groups, showing a gradient
which reached its highest value in those aged 60–64. An interac-
tion between gender and age was found in the two oldest strata,
reﬂecting a larger increase in rates among men with stabilization
in the oldest strata and a smaller increase among women aged 60–
64 with a moderate reduction in the oldest age group. Estimates of
marginal effects on participation are, hence, presented separately
by gender (Table 3).
Table 1 | Invited population, age, and sex distribution of participants and tests performed as a result of the screening program.
OC-Sensor FOB Gold Overall
Mean SD Mean SD Mean SD
Age (year) of invited individuals 59.1 5.8 58.6 5.6 58.8 5.7
n % n % n %
Invited population 18,064 100 19,935 100 37,999 100
Participants 11,162 61.8 11,786 59.1 22,948 60.4
Age distribution (year)
50–54 2729 24.5 3163 26.8 5892 25.7
55–59 2711 24.3 3156 26.8 5867 25.6
60–64 3096 27.7 3169 26.9 6265 27.3
65–69 2626 23.5 2298 19.5 4924 21.4
Gender
Male 5187 46.5 5529 46.9 10716 46.7
Female 5975 53.5 6257 53.1 12232 53.3
I-FOBT results
Positive 737 6.6 1,002 8.5 1,739 7.6
Negative 10,416 93.3 10,723 91.0 21,139 92.1
Result not available 9 0.1 61 0.5 70 0.3
Patients with colonoscopy performed 686 93.11 914 91.21 1,600 92.01
Colonoscopic result available 686 93.11 912 91.01 1,5982 91.91
1 Percentages of participants with the I-FOBT test positive;
2 1,576 colonoscopies with conclusive results.
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Table 2 | Results of participation rates and true positive rates by gender, age, and type of kit administered (true positive rates based on 1,576
colonoscopies performed with conclusive results).
Female Male
OC-Sensor FOB Gold Total OC-Sensor FOB Gold Total
Participation rates (%)
Total 65.1 62.6 63.8 58.3 55.6 56.9
Age (year)
50–54 59.5 57.8 58.5 51.0 49.7 50.3
55–59 67.0 63.6 65.2 57.6 55.6 56.5
60–64 69.3 67.2 68.2 63.4 59.9 61.5
65–69 64.9 62.5 63.8 62.8 59.3 61.1
True positive rates (%)
Total 35.2 31.0 32.8 54.3 49.1 51.3
Age (year)
50–54 36.8 32.9 34.2 41.7 36.5 38.3
55–59 33.3 29.6 31.3 52.3 44.5 48.0
60–64 35.4 31.3 32.9 56.9 53.1 54.8
65–69 35.8 30.2 32.9 59.2 57.5 58.3
Table 3 | Influence of the type of kit administered, gender and age on uptake and true positive rates.
Participation rates (%)
Factor AME CI p-Value
Female 6,8 (5.9/7.6) 0.000
Males Females
Factor AME CI p-Value AME CI p-Value
Kit 2.6 (−5.1/10.2) 0.513 2.4 (−4.8/9.6) 0.512
Age (55–59) 6.2 (3.8/8.7) 0.000 6.7 (5.9/13.3) 0.000
Age (60–64) 11.2 (8.5/13.9) 0.000 9.6 (5.9/13.3) 0.000
Age (65–69) 10.7 (6.2/15.1) 0.000 5.1 (1.9/8.3) 0.002
True positive rates
Factor AME CI p-Value
Female −18.3 (−22.1/−14.6) 0.000
Males Females
Factor AME CI p-Value AME CI p-Value
Kit 4.1 (−0.4/8.6) 0.074 4.4 (−4.9/13.8) 0.354
Age (55–59) 9.4 (3.5/15.4) 0.002 −3.5 (−11.7/4.7) 0.402
Age (60–64) 16.1 (11.7/20.6) 0.000 −1.7 (−3.6/0.3) 0.096
Age (65–69) 19.6 (11.4/27.7) 0.000 −2.0 (−12.8/8.9) 0.721
Results are presented separately for men and women as there was evidence of interaction between gender and age. AME, average marginal effects; CI, 95%
conﬁdence intervals. Reference groups are males and 50–54 years age group.
OUTCOMES WITH FECAL OCCULT BLOOD TESTING
Positive rate for OC-sensor was 6.6 and 8.5% for FOB Gold
(RR = 0.77; 95% CI = 0.69–0.87; p = 0.000). FOB Gold had
consistently higher positive rates than OC-Sensor across all age
and sex strata, except for women in the 54–59 year age-group,
where rates were very similar (OC-Sensor 4.6 vs. 4.5% for FOB
Gold).
True positive rates were higher for OC-Sensor across all age-
sex strata (Table 2). Due to age–gender interaction, results are
again shown separately for men and women. Among men this
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difference among kits was statistically signiﬁcant on the relative
scale (RR = 1.07; 95% CI = 1.00–1.14) and marginally signiﬁcant
on absolute scale (Table 3). Among women differences were not
statistically signiﬁcant on either scale (RR = 1.04; 95% CI = 0.84–
1.29). Increasing agewas signiﬁcantly associatedwith substantially
higher positive rates only among men (Table 3).
Signiﬁcant differences were found between the compared kits
in relation to the total number of errors [error rate for OC-Sensor
0.24% and for FOB Gold 2.35%, AME: −2.1 (−0.2/−4.0)]. Being
female was marginally associated to a lower error rate [RR = 0.85
(0.72–1.01), p = 0.06]. Increasing age was also associated to a
higher error rate. Again there was interaction between age and sex,
with the highest risk in men of 60–64 years of age [RR = 1.62
(1.36–1.92)] and in women of the 65–69 years stratum [RR = 2.14
(1.71–2.67)]. Most of the errors found in the case of FOB Gold
were produced as a result of an incorrect sample manipulation by
the participants.
OUTCOMES WITH COLONOSCOPY
The results of the colonoscopies are shown in Table 4. No signiﬁ-
cant differences were observed between OC-Sensor and FOB Gold
groups. Although 80%of cancers detected in theOC-Sensor group
were early cancers (stages I–II) vs. 56.8% in the FOB Gold group,
due to the small number of malignancies detected, this difference
was not statistically signiﬁcant.
Table 5 shows the detection rates of advanced adenomas and
cancerous lesions among screening participants. FOB Gold assay
users showed higher rates overall and in most age-sex strata. Sta-
tistically signiﬁcant interactions were found between type of kit
and gender with age strata and, in order to ease interpretation of
results, marginal predicted rates are used. Differences in marginal
predictions were highly statistically signiﬁcant according to type
of kit assay (p = 0.000) with almost 10 more lesions detected with
FOBGold per 1,000 participants as compared toOC-Sensor. Being
female was also strongly associated with a lower detection of pre-
malignant and malignant lesions (p = 0.000) whereas increasing
age was signiﬁcantly associated with consistently higher detection
rates (p = 0.000; Table 5).
DISCUSSION
When a population-based screening program is to be imple-
mented, one key issue to deal with is selection of the screening
test to use. In the Basque Country initial decision considered that
the population-based CRC screening program was to be based on
I-FOBT. Accordingly, in the context of a progressive implementa-
tion of the CRC population-based program, a quasi-experimental
study has been carried out aimed to compare the diagnostic accu-
racy and operational characteristics of the two available marketed
I-FOBT tests, FOB Gold and OC-Sensor. Manufacturers’ recom-
mended cut-off levels have been used (Vilkin et al., 2005; Rubeca
et al., 2006; Levi et al., 2007). In our study, several remarkable dif-
ferences have been found between the diagnostic kits compared.
It may be possibly attributable to differences in the quantity of
buffer and other features (NHS Purchasing and Supply Agency,
2009; Moss et al., 2010).
Overall participation rate (60.4%) in this pilot program is
well above the minimum acceptable recommended (Segnan et al.,
2011) and similar or higher than reported rates in other pilot or
established screening programs (UK Colorectal Cancer Screening
Pilot Group, 2004; Department of Health, 2006; Málaga López
et al., 2010). This may be partly attributed to the use of an invi-
tation approach based on mail contact with the target population
that included sending the fecal sampling kit (VanRoosbroeck et al.,
2012). Participation rates were almost 7% higher in women and
increased with aging in both sexes reaching a peak in the 60–
64 age group. This result is in agreement with most but not
Table 4 | Results of the colonoscopies and stage distribution of diagnosed cancers.
OC-Sensor FOB Gold
n % 95% CI n % 95% CI p-Value
Normal 201 29.3 25.8–32.8 302 33.1 30.1–36.3 n.s
Polyp 39 5.7 4.0–7.7 52 5.7 4.3–7.4 n.s
Not advanced adenoma 106 15.4 12.8–18.3 156 17.1 14.7–19.7 n.s
Advanced adenoma 282 41.1 37.4–44.9 338 37.1 33.9–40.3 n.s
Cancer* 35 5.1 3.6–7.0 44 4.8 3.6–6.5 n.s
Stage I 18 51.4 35.1–67.5 17 38.6 24.4–54.5 n.s
Stage II 10 28.6 15.5–45.0 8 18.2 8.2–32.7 n.s
Stage III 6 17.1 7.2–32.3 13 29.5 16.8–45.2 n.s
Stage IV 1 2.9 0.7–14.9 5 11.4 3.8–24.6 n.s
Unknown 0 0 0–10.0 1 2.3 0.06–12.0 n.s
Non-neoplasic pathology 8 1.2 0.5–2.2 9 1.0 0.4–1.9 n.s
Inconclusive 15 2.2 1.2–3.6 11 1.2 0.6–2.1 n.s
Total 686 100 – 912 100 –
n.s., non-signiﬁcant. *Percentages for stages of cancer are based on the total number of cancers instead of total number of colonoscopies.
www.frontiersin.org January 2014 | Volume 4 | Article 175 | 5
“fphar-04-00175” — 2014/1/9 — 10:46 — page 6 — #6
Zubero et al. Choosing I-FOBT for colorectal cancer screening
Table 5 | (a) advanced adenoma and (b) cancer detection incidence rates according to gender, age group, and kit assay; (c) estimated marginal
predictions of advanced adenomas and cancer detection rates according to gender, age group, and kit assay (based on health-district adjusted
log binomial regression model including interactions between kit and gender with age group).
Female Male
OC-Sensor FOB Gold Total OC-Sensor FOB Gold Total
(a) Advanced adenoma detection rates (‰)
Total 12.6 14.3 13.4 39.8 45.1 42.5
Age (year)
50–54 8.3 12.9 10.8 18.6 35.9 21.5
55–59 13.1 11.9 12.5 44.6 35.9 39.9
60–64 11.9 14.8 13.0 45.3 55.6 50.5
65–69 17.2 18.8 17.9 51.0 70.7 60.4
(b) Cancer detection rates (‰)
Total 2.0 2.4 2.2 4.4 5.2 4.8
Age (year)
50–54 1.4 2.9 2.2 0.8 2.7 1.8
55–59 1.4 0.6 0.9 0.8 5.4 3.3
60–64 1.8 3.0 2.4 7.1 2.7 4.8
65–69 3.6 3.4 3.5 8.9 11.6 10.2
(c) Marginal predicted detection rates (‰)









FOB Gold 50.6 49.0–52.3
OC-Sensor 40.8 37.9–43.8
all FOBT-based screening programs conducted in Europe and
Australia (Von Euler-Chelpin et al., 2010; Australian Institute of
Health and Welfare, 2012). There was a signiﬁcant decline in par-
ticipation among women of the oldest group, but not among
men. Other papers have reported a drop in participation rates
in oldest age groups as well (Von Euler-Chelpin et al., 2010).
This ﬁnding cannot be compared with results from the single
published randomized comparison of diagnostic performance of
both tests (Rubeca et al., 2006) as participation required using
both diagnostic kits simultaneously. However, one of the main
strengths of our study is that it was conducted in standard of care
conditions.
The use of OC-Sensor assay resulted in a consistently
increased but not statistically signiﬁcant absolute participation
rates of around 2–3% which might have actual practical rel-
evance though. Gender and age-related participation patterns
were similar for both assays. As we did not survey partici-
pants or qualitatively analyzed on individual characteristics or
potentially relevant operational issues such as ease of use of
received kits or other factors, we cannot make any conclu-
sive statement about the reasons for this observed differences.
Rates of positive tests were higher than referred in most screen-
ing programs that employed any of these tests with 100 ng/ml
as cut-off level on average-risk individuals (Castiglione et al.,
2002; Rubeca et al., 2006). Rates were signiﬁcantly higher among
FOB Gold users which resulted in this group undertaking an
increased amount of colonoscopies (26% increases) compared
to OC-Sensor users. These results are in conﬂict with the
work by Rubeca et al. (2006) which found slightly higher posi-
tive diagnostic rates among OC-Sensor users. Several screening
strategies have established different cut-off points for posi-
tive results using OC-Sensor assay (Van Rossum et al., 2009;
Wilschut et al., 2011; Faivre et al., 2012), 50–75 ng/ml, but in
our population, based on observed positivity rates, lowering the
cut-off may not be appropriate without careful consideration
of the amount of extra resources (colonoscopy and pathology
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procedures) involved and the iatrogenic consequences of false
positives.
With regard to true positive rates (positive predictive values),
several results are remarkable. First of all, true positive rates were
much higher among men across all age strata. Secondly the use
of OC-Sensor assay was associated with higher rates. The higher
percentage of participation found among women when compared
to men across all age levels is according with other studies (UK
Colorectal Cancer Screening Pilot Group, 2004; Department of
Health, 2006; Málaga López et al., 2010; Moss et al., 2010). Par-
ticipation with OC-Sensor was higher than with FOB Gold, for
both sexes and across all age groups, but this differences were not
statistically signiﬁcant when the health-district unit of assignment
was considered in the analysis.
With respect to the relationship between age and participa-
tion, most studies indicated an inverted “U” shaped function with
lowest rates of participation in 50–55 years old and those 70–80
(Australian Institute of Health and Welfare, 2012; Faivre et al.,
2012). Our results, although do not include individuals 70 years
of age and older, seem to be in agreement with this functional
relationship.
A differential gender pattern of true positive responses was
found. Whereas among women neither age nor the kit utilized
inﬂuenced the probability that a positive result was in fact due
to a premalignant or malignant lesion detectable by colonoscopy,
among men increasing age and the use of OC-Sensor kit were
associated to a higher prevalence of true positives.
We have also observed that gender and age are related to dif-
ferences in the detection rates of advanced adenomas and cancer;
with higher rates in men and higher rates by age group. We have
observed that in our population detections rates of adenomas are
higher than in other studies (Bartus, 2005;Vilkin et al., 2005; Smith
et al., 2006). When we analyze the results by type of kit with FOB
Gold we can conclude that: on the one hand, it has higher rate of
positive values, with more colonoscopies performed, and on the
other hand, it shows higher detection rate but involves more false
positives.
We believe the strengths of this study include quasi-
experimental design, comparison of two I-FOBT tests following
manufacturer’s recommendations.
Possible Limitations of the study: (i) cluster randomized design
with small number of clusters leading to baseline imbalance (but
we have used analytical techniques that take clustering effect into
consideration) (ii) lack of measurement on potentially impor-
tant covariates either at individual level (socioeconomic level,
education, etc.) or at cluster level (deprivation index, ethnic
distribution, etc.). As a result there might be important pre-
dictors confounding the estimates of effect of the type of kit
used. The characteristics of the baseline population in the Basque
Country (homogeneity) and the randomization of the assign-
ment of the kits could counterbalance the effects of this lack of
measurement.
CONCLUSION
OC-Sensor test appears to be superior for I-FOBT-based CRC
screening, given its acceptance, ease of use, associated small num-
ber of errors and its screening accuracy. The goal of screening
programs is the early detection and removal of neoplasms and,
above all, the secondary prevention of colorectal cancer in the gen-
eral population. Although the interval cancer period is required to
establish a proper comparison, the advantages found in this anal-
ysis are consistent and lead to the selection of OC sensor as the kit
to be used in the CRC population-based program in our region.
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